Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Elexacaftor · Trikafta, VX-445

Small molecule · Modulator of CFTR · developed by Vertex Pharmaceuticals

Approved FDA

VRTX Developer

1 Registered trials

What is Elexacaftor?

Elexacaftor is a small-molecule CFTR modulator that binds to CFTR protein and facilitates its cellular processing and trafficking to the cell surface. Combined with tezacaftor and ivacaftor in TRIKAFTA, it increases CFTR quantity and function, enhancing chloride transport in patients with cystic fibrosis who carry responsive CFTR variants.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Trikafta, VX-445, ELX/TEZ/IVA
Drug type: Small molecule
Targets: CFTR
Mechanism: Modulator of CFTR
Pathways: CFTR-mediated chloride transport
Therapy area: Respiratory
Developer: Vertex Pharmaceuticals Incorporated (VRTX)
FDA status: Approved as Trikafta, NDA212273 · FDA label
UNII: RRN67GMB0V

✅ FDA-approved uses

Cystic fibrosis

From the indications section of the FDA label (version of Jun 22, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06460506	Phase 3	Cystic Fibrosis	Active not recruiting	VRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cystic Fibrosis

Other drugs acting on CFTR

Deutivacaftor FDA approved Ivacaftor FDA approved Tezacaftor FDA approved Vanzacaftor FDA approved

More from Vertex Pharmaceuticals

Deutivacaftor FDA approved Exagamglogene Autotemcel FDA approved Ivacaftor FDA approved Suzetrigine FDA approved Tezacaftor FDA approved Vanzacaftor FDA approved Inaxaplin Phase 2/3 Povetacicept Phase 2/3 VX-017 Phase 3 VX-118 Phase 1 VX-264 Phase 1/2 VX-272 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the VRTX page.

Follow VRTX, the company behind Elexacaftor

See VRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z